Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACB2112
- Development stage
- Preclinical
- Lead developer
- AC Bioscience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ACB2112 is a novel small molecule drug candidate being developed by AC BioScience, a Swiss biotechnology company based at the Biopôle life sciences campus. The drug is specifically designed to enhance the efficacy of immune-checkpoint inhibitors (ICIs) in the treatment of colorectal cancer (CRC). ACB2112 targets the Wnt/beta-catenin signaling pathway, which is a key driver of immune exclusion and resistance to immunotherapy in CRC. By inhibiting this pathway, ACB2112 aims to transform "cold" tumors into "hot" tumors, thereby sensitizing them to PD-1/PD-L1 blockade and improving clinical outcomes for patients who are currently resistant to existing ICI therapies.
02
Targets
CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on ACB2112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACB2112.